Geovax Labs, Inc. (GOVX) SEC Filing 10-Q Quarterly report for the period ending Tuesday, March 31, 2020

SEC Filings

Geovax Labs, Inc.

CIK: 832489 Ticker: GOVX

Exhibit 99.1


GeoVax Reports 2019 Year-End Financial Results

And Provides Corporate Update


Recent Pivot to COVID-19 Vaccine Development;

Continued Advancements in Other Infectious Disease and Immuno-Oncology Programs


ATLANTA, GA, March 25, 2020 – GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced its financial results for the year ended December 31, 2019 and provided an update on its corporate development progress.


David Dodd, President & CEO, commented, “During the past year and the early months of 2020, GeoVax made substantial progress in various areas of product development. This was combined with tough capital restructuring decisions that, while painful at the time, have now resulted in GeoVax being better positioned for future financing efforts in support of our programs and increasing shareholder value. I am pleased to share a few highlights here.”


Coronavirus Vaccine – In January 2020, we announced our initiation of efforts to develop a vaccine against novel coronavirus disease (COVID-19) caused by the SARS-Cov-2 coronavirus including a letter of intent for a collaboration with BravoVax, a vaccine developer in Wuhan, China. On March 18, 2020, we provided an update on the progress of our program, including the completion of three vaccine candidates and plans for advancing to human clinical trials. Our vaccine has been added to the “Draft Landscape of COVID-19 Candidate Vaccines” by the World Health Organization (

link). We will continue to provide updates on our progress with this very important program.


Cancer Immunotherapy – In September 2019, we incorporated Immutak Oncology, Inc as a wholly-owned subsidiary of GeoVax. We established Immutak to focus on the advancement of our immuno-oncology programs and to seek additional, complementary technologies and clinical-stage products in the oncology space. We intend to leverage the work completed and ongoing with our collaborators at the University of Pittsburgh, ViaMune, Leidos, and others, and have initiated a separate financing effort in support of these programs. We believe developing our programs in this area to be a key component for strengthening the valuation of GeoVax and providing future value growth opportunity.


HIV Vaccines (Therapeutic) – We are participating in a planned clinical trial led by researchers at American Gene Technologies (AGT) to develop a therapy aimed at eliminating HIV from infected people (a “functional cure”). In late 2019, AGT submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its lead HIV program, AGT103-T, a lentiviral vector-based gene therapy. Upon clearance by the FDA, this IND will allow AGT to initiate a Phase 1 clinical trial that will investigate the safety of AGT103-T in humans, measure key biomarkers, and explore surrogate markers of efficacy. GeoVax will provide our novel MVA-VLP-HIV vaccine (MVA62B) for evaluation in an arm of the clinical trial in combination with AGT103-T. AGT has recently stated their intention to begin recruiting patients for the Phase 1 study in mid-2020.


In November 2019, we entered into an agreement with the University of California, San Francisco (UCSF), whereby we will participate in a collaborative effort to develop a combinational therapy aimed at inducing remission in HIV-positive individuals (another approach toward a “functional cure”). The studies will be conducted with funding from amfAR, The Foundation for AIDS Research. The proposed clinical trial will enroll 20 HIV-infected adults who are on stable and effective anti-retroviral therapy (ART) and will involve a combination of vaccines, drugs and biologics. As with the AGT trial, GeoVax will provide MVA62B for use in the studies. Patient enrollment for the clinical trial is expected to commence during 2020.


HIV Vaccines (Preventive) – The development of our preventive HIV vaccine (GOVX-B11) from preclinical studies to human clinical trials has been financially supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The HIV Vaccine Trials Network (HVTN) with support from NIAID, has conducted multiple human clinical trials of our preventive HIV vaccine candidates, and continues advancing our vaccine in clinical studies. We now are planning for a new Phase 1 human clinical trial (designated HVTN 132) with operational support from the HVTN and funding from the NIAID. The primary objectives of HVTN 132 will be to further assess the safety, tolerability and immunogenicity (elicited antibody responses) of a prime-boost regimen of GOVX-B11, in combination with protein boost vaccines. The start of HVTN 132 has been delayed due to clarification of components other than our vaccine, but we currently expect HVTN to commence patient enrollment in late 2020.



The following information was filed by Geovax Labs, Inc. (GOVX) on Wednesday, March 25, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Geovax Labs, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Geovax Labs, Inc..


Assess how Geovax Labs, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Geovax Labs, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (Current Period Unaudited)
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Cash Flows (Unaudited) (Parentheticals)
Condensed Consolidated Statements Of Changes In Stockholders' Equity (Deficiency) (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Note 1 - Description Of Business
Note 10 - Income Taxes
Note 10 - Income Taxes (Details Textual)
Note 11 - Grants And Collaboration Revenue
Note 11 - Grants And Collaboration Revenue (Details Textual)
Note 12 - Subsequent Events
Note 12 - Subsequent Events (Details Textual)
Note 2 - Basis Of Presentation
Note 2 - Basis Of Presentation (Details Textual)
Note 3 - Significant Accounting Policies And Recent Accounting Pronouncements
Note 4 - Basic And Diluted Loss Per Common Share
Note 4 - Basic And Diluted Loss Per Common Share (Details Textual)
Note 5 - Property And Equipment
Note 5 - Property And Equipment (Tables)
Note 5 - Property And Equipment - Schedule Of Property And Equipment (Details)
Note 6 - Accrued Expenses
Note 6 - Accrued Expenses (Tables)
Note 6 - Accrued Expenses - Schedule Of Accrued Expenses (Details)
Note 7 - Notes Payable
Note 7 - Notes Payable (Details Textual)
Note 8 - Commitments
Note 8 - Commitments (Details Textual)
Note 9 - Stockholders' Equity
Note 9 - Stockholders' Equity (Details Textual)
Note 9 - Stockholders' Equity (Tables)
Note 9 - Stockholders' Equity - Preferred Stock Summary (Details)
Note 9 - Stockholders' Equity - Summary Of Warrants (Details)

Material Contracts, Statements, Certifications & more

Geovax Labs, Inc. provided additional information to their SEC Filing as exhibits

Ticker: GOVX
CIK: 832489
Form Type: 10-Q Quarterly Report
Accession Number: 0001437749-20-009452
Submitted to the SEC: Tue May 05 2020 4:26:25 PM EST
Accepted by the SEC: Tue May 05 2020
Period: Tuesday, March 31, 2020
Industry: Commercial Physical And Biological Research

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: